■覆盖的主动脉分叉腔内重建（CERAB）技术为涉及主动脉分叉的跨大西洋社会间共识（TASC）C/D病变提供了替代方案。该研究旨在使用Begraft球囊扩张覆膜支架（BECS）评估CERAB技术治疗广泛的主动脉闭塞性疾病（AIOD）的结果。
■这是医生发起的，多中心，回顾性,观察性研究。在2017年6月至2021年6月之间，所有使用Begraft支架（BentleyInnoMed，赫辛根,德国）在3个诊所注册。患者人口统计学，病变特征,收集和回顾性分析手术结果.在1、6和12个月进行随访，然后每年进行临床检查，踝肱指数(ABI),和双工超声。主要终点是12个月时的通畅性。次要终点包括手术相关并发症,二级通畅，无靶病变血运重建（TLR），和临床改善。
■总之，分析了120名患者（64名男性），中位年龄为65岁（范围：34-84岁）。大多数患者的广泛AIOD分类为TASCIIC（n=32；26.7％）或TASCIID（n=81；67.5％）。手术的中位持续时间为120分钟(四分位距[IQR]:80-180分钟)。所有454个Begraft支架(137个主动脉和317个外周)均成功递送和部署。手术并发症总发生率为14例(11.7%)。中位住院时间为5天（IQR：3-6天）。所有患者临床好转，ABI显著升高(p<0.05)。中位随访时间为19个月(6～56个月)。主要通畅率，二级通畅率，12个月时的TLR自由度为94.5%，97.3%,93.5%,分别。
■使用BegraftBECSs的CERAB程序具有很高的技术成功率，良好的通畅结果，低发病率，即使在患有广泛AIOD的相对疾病的患者中。绝对建议对CERAB技术进行前瞻性随机研究。
结论：本研究评估了覆膜血管内重建主动脉分叉（CERAB）手术期间使用Begraft支架的结果。迄今为止,几种球囊扩张覆膜支架已用于该技术，结果令人满意。这项研究显示了CERAB技术在使用Begraft球囊扩张覆膜支架的广泛AIOD中的安全性和出色的通畅性。
UNASSIGNED: The covered endovascular reconstruction of the aortic bifurcation (CERAB) technique offers an alternative for Trans-Atlantic Inter-Society Consensus (TASC) C/D lesions involving the aortic bifurcation. The
study aims to evaluate the outcomes of the CERAB technique for extensive aortoiliac occlusive disease (AIOD) using the BeGraft balloon-expandable covered stent (BECS).
UNASSIGNED: This is a physician-initiated, multicenter, retrospective, observational
study. Between June 2017 and June 2021, all consecutive patients who underwent the CERAB procedure using the BeGraft stent (Bentley InnoMed, Hechingen, Germany) in 3 clinics were enrolled. Patients\' demographics, lesion characteristics, and procedural results were collected and retrospectively analyzed. Follow-up was done at 1, 6, and 12 months and then annually with clinical examination, ankle-brachial index (ABI), and duplex ultrasound. The primary endpoint was the patency at 12 months. Secondary endpoints included procedural-related complications, secondary patency, freedom from target lesion revascularization (TLR), and clinical improvement.
UNASSIGNED: In all, 120 patients (64 men) with a median age of 65 years (range: 34-84 years) were analyzed. Most patients had extensive AIOD classified as TASC II C (n=32; 26.7%) or TASC II D (n=81; 67.5%). The median duration of the procedure was 120 minutes (interquartile range [IQR]: 80-180 minutes). All 454 BeGraft stents (137 aortic and 317 peripheral) were successfully delivered and deployed. The overall procedural complication rate was 14 (11.7%). The median hospital length of stay was 5 days (IQR: 3-6 days). All patients improved clinically, and the ABI increased significantly (p<0.05). The median follow-up was 19 months (range: 6-56 months). The primary patency rate, secondary patency rate, and freedom from TLR at 12 months were 94.5%, 97.3%, and 93.5%, respectively.
UNASSIGNED: The CERAB procedure with BeGraft BECSs has a high technical success rate, favorable patency outcomes, and low morbidity, even in relatively ill patients with extensive AIOD. Prospective randomized studies on the CERAB technique are definitely recommended.
CONCLUSIONS: This
study evaluates the outcomes of BeGraft stents used during the covered endovascular reconstruction of the aortic bifurcation (CERAB) procedure. To date, several balloon-expandable covered stents have been used for this technique with satisfactory results. This
study showed the safety and excellent patency of the CERAB technique in extensive AIOD using BeGraft balloon-expandable covered stents.
